Company: CRL
Filing Date: 2025-11-05
Form Type: 10-Q
Source: 0001100682-25-000043
Chunk: 36

Company: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
Filing Date: 2025-11-05
Form: 10-Q
Item: Item 2
Chunk 36
---
RMS$113,944 $100,641 $13,303 13.2 %0.9 %DSA339,886 379,651 (39,765)(10.5)%1.5 %Manufacturing43,367 111,099 (67,732)(61.0)%0.7 %Unallocated corporate(188,595)(196,357)7,762 (4.0)%0.2 %Total operating income$308,602 $395,034 $(86,432)(21.9)%1.8 %Operating income % of revenue10.2 %13.0 %(280) bps

The following presents and discusses our consolidated financial results by each of our reportable segments:

RMS

Nine Months EndedSeptember 27, 2025September 28, 2024$ change% changeImpact of FX(in thousands, except percentages)Revenue$639,818 $625,120 $14,698 2.4 %0.5 %Cost of revenue (excluding amortization of intangible assets)430,435 421,773 8,662 2.1 %Selling, general and administrative77,509 84,943 (7,434)(8.8)%Amortization of intangible assets17,930 17,763 167 0.9 %Operating income$113,944 $100,641 $13,303 13.2 %0.9 %Operating income % of revenue17.8 %16.1 %170 bps

RMS revenue increased $14.7 million primarily driven by increases in large research model product revenue, notably from Noveprim, small model product revenue in Europe and China, GEMS and Insourcing Solutions service revenue, and the effect of changes in foreign currency exchange rates; partially offset by a decrease in Cell Supply product revenue.

RMS operating income increased $13.3 million compared to the corresponding period in 2024. RMS operating income as a percentage of revenue for the nine months ended September 27, 2025 was 17.8%, an increase of 170 bps from 16.1% for the corresponding period in 2024. Operating income and operating income as a percentage of revenue increased primarily due to the higher revenue described above, lower charges related to restructuring activities, including asset impairments and site 

32